Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer

Background HMGB1 (high mobility group box B-1) exhibits crucial role in tumor genesis and development, including lung cancer.

Whereas, more HMGB1-related details in non-small cell lung cancer (NSCLC) are still largely unclear.

Methods The HMGB1 and inflammatory factors in malignant (MPE) and non-malignant pleural effusion (BPE) were determined by ELISA.

Additionally, qRT-PCR, western blot, or immunohistochemistry were used to determine HMGB1, drug-resistant and apoptotic proteins’ expressions in NSCLC A549, A549-DDP cell lines, and xenograft model.

Cell viability, migration/ invasion, and apoptosis were analyzed using MTT, Transwell, and flow cytometry assays, respectively.

Results Inflammatory factors and HMGB1 expressions in MPE were significantly higher than BPE of NSCLC.

Compared with preoperative and adjacent tissues, significantly higher HMGB1, drug-resistant protein, and anti-apoptotic protein expressions were observed in recurrent tissues.

Overexpressed HMGB1 induced NSCLC cells to exhibit stronger aggressive, proliferative, and drug-resistant features.

The related abilities were reversed when HMGB1 was interfered.

Overexpressed HMGB1 showed a similar co-localization with drug resistant protein P-gp in cytoplasm in xenograft model, while low HMGB1 expression localized in cell nucleus.

Conclusions HMGB1 overexpression significantly promoted the malignant progression and cisplatin resistance of NSCLC in vitro and in vivo.